免疫检查点抑制剂的疗效预测标志物

针对程序性死亡受体1(programmed death receptor 1,PD-1)/程序性死亡受体配体1(programmed death receptor ligand 1,PD-L1)通路的免疫检查点抑制剂（immune checkpoint inhibitors,ICI）的研究十分热门，为多种晚期肿瘤患者的治疗提供了新的希望。然而，ICI的有效率仍偏低，非目标患者对其没有应答，部分患者会出现延迟反应、假性进展等特殊应答模式，目前尚无精准的疗效预测标志物能够提前对患者的肿瘤反应及预后做出判断，使得患者在应用免疫检查点抑制剂时受到限制，本文对目前常用及部分近期研究的疗效预测标志物进行简要综述。

Predictive biomarkers of immune checkpoint inhibitor

The study of immune checkpoint inhibitors(ICI)targeting programmed death receptor 1(PD-1)/programmed death receptor ligand 1(PD-L1)pathway is very hot,providing new hope for the treatment of a variety of patients with advanced cancer.However,the effective rate of ICI is still low.Non-target patients do not respond to it,and some patients will have special response patterns such as delayed response and pseudoprogression.At present,there is no accurate efficacy predictor that can make a judgment on the tumor response and prognosis of patients in advance,which greatly limits the clinical application of immune checkpoint inhibitors.In this paper,we briefly review the efficacy predictive markers commonly used and recently studied.